Clinical Research Directory
Browse clinical research sites, groups, and studies.
Genotypic Influences on Network Progression in Parkinson's Disease
Sponsor: Northwell Health
Summary
In this longitudinal study, the investigators will follow Parkinson's disease (PD) patients with and without glucocerebrosidase (GBA) mutations. The investigators hypothesize that the rate of increase in brain network activity over time (network progression rate) is faster in patients with GBA gene mutations.
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
32
Start Date
2020-02-24
Completion Date
2026-02-01
Last Updated
2025-12-18
Healthy Volunteers
No
Conditions
Interventions
DNA/GeneticTesting
Subjects will be tested for GBA and LRRK2 mutation status at baseline.
FDG PET scan
18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
MRI scan
Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
Clinical and neuropsychological assessments
Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
Locations (1)
Feinstein Institutes for Medical Research
Manhasset, New York, United States